ArticleJournal of Parkinson's disease2026
Insights and priorities from the 2025 private funders' Parkinson's disease and related disorders large footprint data interoperability summit.
Article in Journal of Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective sharing of large datasets across traditionally siloed research domains has the power to transform conventional research practice dramatically, but has been stymied by persistent barriers to data access and interoperability. The 2025 Private Funders' Parkinson's Disease and Related Disorders (PDRD) Data Interoperability Summit brought together technical leaders from North American-based private funders and research organizations engaged in large-scale neurodegenerative data efforts to address these challenges through the lens of FAIR (Findability, Accessibility, Interoperability, and Reusability) principles. Pre-summit activities included structured interviews, comprehensive data assessments, and preparatory exercises to identify common pain points, systemic gaps, and areas of opportunity across the data ecosystem. During the summit, participants collaboratively developed and prioritized a suite of actionable recommendations, underscoring the urgency and complexity of improving the neurodegenerative data ecosystem. Despite facing significant technical, legal, regulatory, and cultural barriers - ranging from high data management costs and privacy concerns to fragmented governance structures - participants expressed strong alignment on the need for strategic, equitable, and collaborative solutions. Here, we summarize the emerging recommendations from those discussions as well as the high-priority initiatives selected for immediate action across the funding agencies. These efforts mark a critical first step in addressing longstanding barriers and reflect a shared commitment to advancing collaborative data sharing. Continued work in this area promises to accelerate discovery and innovation, with the potential to drive significant breakthroughs in the understanding, diagnosis, and treatment of neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.